Update on malignant ovarian germ cell tumors

摘要: The evolution of therapy for malignant ovarian germ cell tumors has been one the true success stories in oncology. This article reviews major advances this field, with emphasis on more recent developments. During past two decades, nomenclature and histologic criteria subtypes have standardized. Although role secondary debulking is uncertain, it probably merit selected patients. use second-look laparotomy should be limited as much possible. Chemotherapeutic regimens evolved to current “gold standard” —the combination bleomycin, etoposide, cisplatin, overall disease-free survival rates greater than 95%. For patients metastatic dysgerminoma, chemotherapy replaced radiation treatment choice. those few who do not respond first-line therapy, vinblastine, ifosfamide, cisplatin most popular regimen subset platinum-sensitive tumors. platinum-resistant tumors, dose intensification autologous bone marrow rescue or Phase II drugs are being investigated. Studies late effects reveal that reproductive potential can preserved young In summary, although progress field phenomenal, small incremental will continue occur during 1990s.